Skip to content
Head to head

Vaxcyte vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: PCVX · VRTX

Updated 7 minutes ago

1-year performance, rebased to 100

PCVX +14.6%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
PCVXVRTX
Snapshot
Sector--Biotechnology
Last price55.39515.02
Change today-5.09%-1.08%
1-year return+16.2%+22.0%
Market cap$8.77B$130.58B
52-week range42.40 – 90.75412.27 – 568.67
Valuation
P/E (TTM)-6.8833.14
P/E percentile, own 5-yr range92nd99th
P/B3.526.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-5.6315.32
Net profit (TTM)$-891.23M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)$-994.76M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership112.9%96.8%
Insider activity (12mo)16 buy / 33 sell28 buy / 22 sell
Short interest (% of float)9.8%1.9%
Analyst consensus89% buy / 11% hold (9)95% buy / 5% hold (21)
Analyst price target$116 (+109%)$624 (+21%)
StockVane view
StockVane Quant RatingD (58)C (68)
Company
Employees5076,400
Founded20131989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.